Hematologic Oncology

The phase III ALCYONE study showed that daratumumab in combination with bortezomib, melphalan, and prednisone is a viable front-line option for myeloma patients who are not candidates for ASCT.

The FDA has released a statement regarding safety concerns that led to a clinical hold on three trials of pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma, and the active role of the FDA in protecting patient safety.

Researchers at St. Jude Children’s Research Hospital have discovered a vulnerability that may easily translate into new targeted drug therapies that block heme biosynthesis, killing leukemic cells.

This video highlights patient variables, including kidney function or history of diabetes, that can help guide treatment in chronic myeloid leukemia.

In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.

Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.

Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo.

Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States.

A new study indicates that patients with primary immunodeficiency diseases may be at a much higher risk for certain cancers, especially lymphoma.

This video highlights novel approaches using immunotherapies and vaccines for advancing treatment in multiple myeloma.

Arsenic trioxide consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia and allowed for significant reductions in cumulative anthracycline doses.

Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.

The US Food and Drug Administration has approved the tyrosine kinase inhibitor ibrutinib (Imbruvica) for adult patients with chronic graft vs host disease who have failed on one or more lines of prior systemic therapy.

The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes.

The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.

Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study.

A lower dose of rabbit anti–T-lymphocyte globulin was superior to a higher dose in children with hematologic malignancies undergoing transplant from an unrelated donor.

The FDA has approved the marketing of a new lab test used with flow cytometry to aid in the detection of several types of hematologic malignancies.

A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.

Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.

Treatment of adult relapsed or refractory acute lymphoblastic leukemia with inotuzumab ozogamicin was associated with increased hepatotoxicity, especially after follow-up hematopoietic stem cell transplantation.

The FDA placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma.

In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.

The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.

ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.

Patients with high-risk diffuse large B-cell lymphoma had a reduced risk of treatment failure, but no survival improvement, with an abbreviated course of rituximab-dose-dense chemotherapy plus high-dose chemotherapy and transplant compared with a full course of chemotherapy.